Yasuto Yoneshima
Fukuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.
Journal: Future oncology (London, England)
Published: July 16, 2026
Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.
Journal: ESMO open
Published: June 06, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
Journal: JCO precision oncology
Published: June 04, 2025
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer.
Journal: Translational lung cancer research
Published: June 03, 2025
Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report.
Journal: Respiratory medicine case reports
Published: March 26, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: March 25, 2025
IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.
Journal: Molecular cancer
Published: February 25, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 07, 2025
Renal dysfunction during osimertinib treatment in patients with non-small cell lung cancer positive for EGFR mutations.
Journal: Respiratory investigation
Published: December 12, 2024
Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis.
Journal: Journal for immunotherapy of cancer
Published: November 28, 2024
Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.
Journal: British journal of cancer
Published: November 27, 2024
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors.
Journal: Cancer immunology, immunotherapy : CII
Published: November 26, 2024
Last Updated: 09/26/2026